is for Kids
E is for Efficacy
" Lev adjunctive therapy is efficacious and well tolerated in children with treatment resistant partial seizures."Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.
Glauser TA et al., Neurology. 2006 Apr 26;
- Seizure freedom in refactory patients aged 4-16 years (14-week
treatment period)
(Glauser TA, Gauer LJ, Chen L, et at. Epilepsia. 2004;45 (suppl):186)
-
Keppra demonstrated efficacy in a population of patients aged 4-16 years that included partial-seizure types: simple partial, complex partial, and secondary generalized
(Glauser TA, Gauer LJ, Chen L, et at. Epilepsia. 2004;45 (suppl):186) (Data on file. UCB Pharma, Inc) - 45% of refractory patients aged 4-16 years responded to treatment
(Glauser TA, Gauer LJ, Chen L, et at. Epilepsia. 2004;45 (suppl):186) - Significant reduction of partial onset seizures
(Glauser TA, Gauer LJ, Chen L, et at. Epilepsia. 2004;45 (suppl):186)
S is for Safety
- Favourable tolerability profile confirmed
(Data on file. UCB Pharma, Inc) - Incidence of most common adverse events in Phase III paediatric trial
(Data on file. UCB Pharma, Inc)
- Low discontinuation or dose-reduction rates due to an adverse
event in patients aged 4-16 years-16.8% vs 20.6% placebo
(Data on file. UCB Pharma, Inc) - No known clinically significant drug interactions in this well-controlled study
In another study of 39 paediatric patients with epilepsy
- 26% noted improvement in behaviour and/or cognition after
Keppra was added to the AED regimen
(Wheless JW, Ng Y. Levetiracetam in refractor pediatric epilepsy. J Child Neurol. 2002;17:412-415)
- Improvements included: increased cognition/concentration,
increased alertness, and improved behaviour
(Wheless JW, Ng Y. Levetiracetam in refractor pediatric epilepsy. J Child Neurol. 2002;17:412-415)
